Computational Immunobiology Core

计算免疫生物学核心

基本信息

  • 批准号:
    10622057
  • 负责人:
  • 金额:
    $ 82.76万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2017
  • 资助国家:
    美国
  • 起止时间:
    2017-08-15 至 2028-04-30
  • 项目状态:
    未结题

项目摘要

ABSTRACT – Computational Immunobiology Core The Computational Immunobiology Core (CIC) will provide comprehensive technical assay support services and analytic support for the hypothesis-driven research studies proposed in the two Projects comprising this U19 proposal. The Core derives its greatest overall strength from its intersection of technical and transplant- specific expertise, state-of-the art methods for multidimensional biological interrogation, and explicit proficiency in advanced computational analytics. Led by Dr. Kirk, the Core continues to utilize the longstanding assets of prior iterations of this program to achieve comprehensive characterization of transplant procedures, with particular expertise in polychromic flow cytometry-based platforms for immune profiling. Assay testing is performed in a Good Clinical Laboratory compliant environment according to highly standardized and validated Standard Operating Procedures, by a team that has been supporting NHP transplant work for over 25 years. To this established team, a new collaboration has been forged with NC State University, an international leader in veterinary medicine, to incorporate a novel platform for comprehensive, rhesus macaque-specific, single cell RNA sequence analysis. This is the first lab to comprehensively provide RNA sequence analysis for the entire TCR and BCR repertoire in the rhesus macaque, and as such, adds unprecedented granularity to the analysis of the in vivo studies proposed in the two Projects. Given the exponential growth in data acquired from these capabilities, new expertise in high-density data analytics has been added through the recruitment of Drs. Peng and Chan. These individuals have extensive expertise in the integration of sequence- and flow-based datasets with traditional metrics of clinical outcome, specifically in nonhuman primate studies. The key services the CIC will provide to Projects 1 and 2 include: 1) state-of-the-art specimen capture, processing, and biobanking; 2) analytical polychromatic flow cytometry phenotyping and intracellular cytokine staining; 3) single cell RNA sequencing; 4) quantitative virologic testing; 5) comprehensive histology and immunohistochemistry support; and 6) computational analysis for the data emerging from the assays. The present core facilities house all the advanced equipment required for turn-key assessment of the proposed primate studies, including exceptional flow and sequencing platforms, and a specimen processing and biobanking service that serves the entire Duke community under Dr. Kirk’s supervision. The established viral testing facility monitors three of the most clinically relevant viruses in transplantation: Rhesus Cytomegalovirus (rhCMV), Rhesus Lymphocryptovirus (rhLCV) (rhesus homology of EBV), and Simian Virus 40 (SV40). The CIC also provides routine histology and immunohistochemistry assays through our immunohistochemistry service laboratory, allowing each project to examine the effects of the experimental manipulations on key donor and host tissues. The juxtaposition of human and NHP expertise represents a particular strength of this IPC consortium, further facilitating the highly translational aspects of the proposed studies.
摘要:计算免疫生物学核心

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Allan D. Kirk其他文献

Anti-IL12/23 synergizes with costimulatory blockade to prolong transplant survival
  • DOI:
    10.1016/j.jamcollsurg.2011.06.162
  • 发表时间:
    2011-09-01
  • 期刊:
  • 影响因子:
  • 作者:
    William H. Kitchens;Andrew B. Adams;Allan D. Kirk;Christian P. Larsen;Mandy L. Ford
  • 通讯作者:
    Mandy L. Ford
Necrosis and immune activation: does tissue death alter acquired alloimmunity?
  • DOI:
    10.1016/j.jamcollsurg.2013.07.331
  • 发表时间:
    2013-09-01
  • 期刊:
  • 影响因子:
  • 作者:
    Salila S. Hashmi;Mandy L. Ford;Christian P. Larsen;Allan D. Kirk
  • 通讯作者:
    Allan D. Kirk
B cells and transplantation tolerance
B 细胞与移植耐受
  • DOI:
    10.1038/nrneph.2010.111
  • 发表时间:
    2010-08-24
  • 期刊:
  • 影响因子:
    39.800
  • 作者:
    Allan D. Kirk;Nicole A. Turgeon;Neal N. Iwakoshi
  • 通讯作者:
    Neal N. Iwakoshi
Assessing Quality of Real-World Data Supplied by an Automated Surgical Data Pipeline
  • DOI:
    10.1016/j.jamcollsurg.2019.08.203
  • 发表时间:
    2019-10-01
  • 期刊:
  • 影响因子:
  • 作者:
    Kristin Corey;Joshua Helmkamp;Allan D. Kirk;Suresh Balu;David Thompson;Leila Mureebe;Joshua Watson;Keith Marsolo;Lesley Curtis;Mark Sendak
  • 通讯作者:
    Mark Sendak
Toll-Like Receptor Signaling as a Prognostic Tool in Trauma Patients
  • DOI:
    10.1016/j.jamcollsurg.2016.06.346
  • 发表时间:
    2016-10-01
  • 期刊:
  • 影响因子:
  • 作者:
    Marcus D. Darrabie;Jaewoo Lee;Jennifer Cheeseman;Alexander T. Limkakeng;Steven N. Vaslef;Bruce A. Sullenger;Allan D. Kirk
  • 通讯作者:
    Allan D. Kirk

Allan D. Kirk的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Allan D. Kirk', 18)}}的其他基金

Advanced Immunobiology Traning Program for Surgeons
外科医生高级免疫生物学培训计划
  • 批准号:
    10598547
  • 财政年份:
    2019
  • 资助金额:
    $ 82.76万
  • 项目类别:
Advanced Immunobiology Traning Program for Surgeons
外科医生高级免疫生物学培训计划
  • 批准号:
    10396460
  • 财政年份:
    2019
  • 资助金额:
    $ 82.76万
  • 项目类别:
Depletion, Repopulation and Tolerance in Non-Sensitied Recipients
非敏感受体的消耗、再生和耐受性
  • 批准号:
    9980790
  • 财政年份:
    2017
  • 资助金额:
    $ 82.76万
  • 项目类别:
Depletion, Repopulation and Tolerance in Non-Sensitied Recipients
非敏感受体的消耗、再生和耐受性
  • 批准号:
    10214495
  • 财政年份:
    2017
  • 资助金额:
    $ 82.76万
  • 项目类别:
Depletion, Repopulation and Tolerance in Non-Sensitied Recipients
非敏感受体的消耗、再生和耐受性
  • 批准号:
    10649945
  • 财政年份:
    2017
  • 资助金额:
    $ 82.76万
  • 项目类别:
Cell Adhesion and Trafficking as a Therapeutic Target in Allotransplantation
细胞粘附和运输作为同种异体移植的治疗靶点
  • 批准号:
    8705985
  • 财政年份:
    2014
  • 资助金额:
    $ 82.76万
  • 项目类别:
T Cell Maturation and the Nexus of Viral- and Allo-Immunity
T 细胞成熟以及病毒免疫和同种异体免疫的关系
  • 批准号:
    8371823
  • 财政年份:
    2012
  • 资助金额:
    $ 82.76万
  • 项目类别:
T Cell Maturation and the Nexus of Viral- and Allo-Immunity
T 细胞成熟以及病毒免疫和同种异体免疫的关系
  • 批准号:
    8463978
  • 财政年份:
    2012
  • 资助金额:
    $ 82.76万
  • 项目类别:
T Cell Maturation and the Nexus of Viral- and Allo-Immunity
T 细胞成熟以及病毒免疫和同种异体免疫的关系
  • 批准号:
    8607811
  • 财政年份:
    2012
  • 资助金额:
    $ 82.76万
  • 项目类别:
ADJUVANT THERAPIES IMPROVING ANTI-REJECTION EFFECTS OF COSTIMULATION BLOCKADE
辅助疗法改善共同刺激封锁的抗排斥效果
  • 批准号:
    8357527
  • 财政年份:
    2011
  • 资助金额:
    $ 82.76万
  • 项目类别:

相似国自然基金

Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
  • 批准号:
    2022J011295
  • 批准年份:
    2022
  • 资助金额:
    10.0 万元
  • 项目类别:
    省市级项目
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
  • 批准号:
    30801055
  • 批准年份:
    2008
  • 资助金额:
    19.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Bovine herpesvirus 4 as a vaccine platform for African swine fever virus antigens in pigs
牛疱疹病毒 4 作为猪非洲猪瘟病毒抗原的疫苗平台
  • 批准号:
    BB/Y006224/1
  • 财政年份:
    2024
  • 资助金额:
    $ 82.76万
  • 项目类别:
    Research Grant
Uncovering tumor specific antigens and vulnerabilities in ETP-acute lymphoblastic leukemia
揭示 ETP-急性淋巴细胞白血病的肿瘤特异性抗原和脆弱性
  • 批准号:
    480030
  • 财政年份:
    2023
  • 资助金额:
    $ 82.76万
  • 项目类别:
    Operating Grants
A novel vaccine approach combining mosquito salivary antigens and viral antigens to protect against Zika, chikungunya and other arboviral infections.
一种结合蚊子唾液抗原和病毒抗原的新型疫苗方法,可预防寨卡病毒、基孔肯雅热和其他虫媒病毒感染。
  • 批准号:
    10083718
  • 财政年份:
    2023
  • 资助金额:
    $ 82.76万
  • 项目类别:
    Small Business Research Initiative
Regulation of B cell responses to vaccines by long-term retention of antigens in germinal centres
通过在生发中心长期保留抗原来调节 B 细胞对疫苗的反应
  • 批准号:
    MR/X009254/1
  • 财政年份:
    2023
  • 资助金额:
    $ 82.76万
  • 项目类别:
    Research Grant
Adaptive Discrimination of Risk of Antigens in Immune Memory Dynamics
免疫记忆动态中抗原风险的适应性辨别
  • 批准号:
    22KJ1758
  • 财政年份:
    2023
  • 资助金额:
    $ 82.76万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
22-ICRAD Call 2 - Improving the diagnosis of tuberculosis in domestic ruminants through the use of new antigens and test platforms
22-ICRAD 呼吁 2 - 通过使用新抗原和测试平台改善家养反刍动物结核病的诊断
  • 批准号:
    BB/Y000927/1
  • 财政年份:
    2023
  • 资助金额:
    $ 82.76万
  • 项目类别:
    Research Grant
Protective immunity elicited by distinct polysaccharide antigens of classical and hypervirulent Klebsiella
经典和高毒力克雷伯氏菌的不同多糖抗原引发的保护性免疫
  • 批准号:
    10795212
  • 财政年份:
    2023
  • 资助金额:
    $ 82.76万
  • 项目类别:
Integrative proteome analysis to harness humoral immune response against tumor antigens
综合蛋白质组分析利用针对肿瘤抗原的体液免疫反应
  • 批准号:
    23K18249
  • 财政年份:
    2023
  • 资助金额:
    $ 82.76万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
Functionally distinct human CD4 T cell responses to novel evolutionarily selected M. tuberculosis antigens
功能独特的人类 CD4 T 细胞对新型进化选择的结核分枝杆菌抗原的反应
  • 批准号:
    10735075
  • 财政年份:
    2023
  • 资助金额:
    $ 82.76万
  • 项目类别:
Targeting T3SA proteins as protective antigens against Yersinia
将 T3SA 蛋白作为针对耶尔森氏菌的保护性抗原
  • 批准号:
    10645989
  • 财政年份:
    2023
  • 资助金额:
    $ 82.76万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了